Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-02-07
Target enrollment:
Participant gender:
Summary
A phase I/II, open-label, study to determine the safety and preliminary efficacy of
orellanine in patients with metastatic clear-cell or papillary renal carcinoma. The study
will include an intra-patient dose escalation phase, followed by a dose expansion phase.